Patent GB515212A successfully refreshed from Google Patents.
US6258121B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stent coating
Assignee: Boston Scientific Scimed Inc
•
Filing: 1999-07-02
•
Granted: 2001-07-10
•
Expires: 2019-07-02
Abstract
Abstract A stent having a polymeric coating for controllably releasing an included active agent. The polymeric coating includes a blend of a first polymeric material, which if alone, would release the agent at a first, higher rate, and a second polymeric material, which if alone would release the agent at a second, lower rate over a longer time period. One stent coating utilizes a faster releasing hydrophilic polymeric material and a slower releasing hydrophobic material. One stent coating includes a blend of a faster releasing PLA-PEO copolymer and a slower releasing PLA-PCL copolymer. One active agent is Taxol. One use of the Taxol delivering stent is to inhibit restenosis following angioplasty.
Inventors
- 👤 Dachuan Yang
- 👤 Joel L. Stanslaski
- 👤 Lixiao Wang
- 👤 Scott R. Smith
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:32
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61L; A61L31/00; A61L31/08; A61L31/10; A61L31/14; A61L31/16; A61P; A61P35/00; A61F; A61F2/00; A61F2/82; A61F2/86; A61F2/90; A61F2/91; A61F2250/00; A61F2250/0058; A61F2250/0067; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/602; A61L2300/606; A61L2300/608
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
95 words
A stent comprising: a stent body; a coating disposed over at least a portion of said body; and a biologically active agent dispersed in said coating, wherein said coating includes a mixture of a first co-polymer and a second co-polymer, wherein said first co-polymer releases said agent at a first rate and said second co-polymer release said agent at a second rate, wherein said second rate is slower than said first rate, such that said agent is released from said coating at a rate slower than said first rate and faster than said second rate.
Claim 2
Dependent Claim
95 words
A stent comprising: a stent body; a coating disposed over at least a portion of said body; and a biologically active agent dispersed in said coating, wherein said coating includes a mixture of a first co-polymer and a second co-polymer, wherein said first co-polymer releases said agent at a first rate and said second co-polymer release said agent at a second rate, wherein said second rate is slower than said first rate, such that said agent is released from said coating at a rate slower than said first rate and faster than said second rate.
Claim 3
Dependent Claim
14 words
A stent as recited in claim 1 , wherein said first co-polymer is hydrophilic.
Claim 4
Dependent Claim
14 words
A stent as recited in claim 1 , wherein said second co-polymer is hydrophobic.
Claim 5
Dependent Claim
20 words
A stent as recited in claim 1 , wherein said first co-polymer is hydrophilic and said second co-polymer is hydrophobic.
Claim 6
Dependent Claim
15 words
A stent as recited in claim 1 , wherein said first co-polymer include s PLA-PEO.
Claim 7
Dependent Claim
14 words
A stent as recited in claim 1 , where said second co-polymer includes PLA-PCL.
Claim 8
Dependent Claim
20 words
A stent as recited in claim 1 , wherein said first co-polymer includes PLA-PEO and said second co-polymer includes PLA-PCL.
Claim 9
Dependent Claim
28 words
A stent as recited in claim 7 , wherein said agent includes an agent selected from the group consisting of paclitaxel, paclitaxel analogues, paclitaxel derivatives, and combinations thereof.
Claim 10
Dependent Claim
107 words
A stent for controllably releasing a biologically active agent over a long time period comprising: a stent body; a biologically active agent; and means for adhering said agent to said stent body and controllably releasing said agent from said stent body over time, wherein said means for controllably releasing said agent includes an admixture of a first means for releasing said agent at a first rate over a first time period and second means for releasing said agent at a second rate over a second time period, wherein said first rate is faster than said second rate and said first period is shorter than said second period.
Claim 11
Dependent Claim
107 words
A stent for controllably releasing a biologically active agent over a long time period comprising: a stent body; a biologically active agent; and means for adhering said agent to said stent body and controllably releasing said agent from said stent body over time, wherein said means for controllably releasing said agent includes an admixture of a first means for releasing said agent at a first rate over a first time period and second means for releasing said agent at a second rate over a second time period, wherein said first rate is faster than said second rate and said first period is shorter than said second period.
Claim 12
Dependent Claim
40 words
A stent as recited in claim 9 , wherein said first means for releasing includes a bioabsorbable polymeric material and second means for releasing includes a bioabsorbable polymeric material, wherein said first means is absorbed faster than said second means.
Claim 13
Dependent Claim
54 words
A stent for releasing a biologically active agent inside the human body comprising: a stent body; a polymeric coating disposed over at least a part of said stent body; and a biologically active material admixed with said polymeric coating, wherein said polymeric coating includes a blend of a PLA-PEO copolymer and a PLA-PCL copolymer.
Claim 14
Dependent Claim
54 words
A stent for releasing a biologically active agent inside the human body comprising: a stent body; a polymeric coating disposed over at least a part of said stent body; and a biologically active material admixed with said polymeric coating, wherein said polymeric coating includes a blend of a PLA-PEO copolymer and a PLA-PCL copolymer.
Claim 15
Dependent Claim
30 words
A stent as recited in claim 11 , wherein said biologically active agent includes an agent selected from the group consisting of paclitaxel, paclitaxel analogues, paclitaxel derivatives, and combinations thereof.
Claim 16
Independent Claim
84 words
A method for inhibiting restenosis comprising the steps of: providing a stent including a coating having a blend of a PLA-PEO copolymer and a PLA-PCL copolymer, wherein said coating includes a restenosis inhibiting agent selected from the group consisting of paclitaxel, paclitaxel analogues, paclitaxel derivatives, and combinations thereof mixed therein, such that said agent is released over a time period longer than would be released by said PLA-PEO copolymer alone, and released over a time period shorter than would be released PLA-PCL copolymer alone.
Claim 17
Independent Claim
84 words
A method for inhibiting restenosis comprising the steps of: providing a stent including a coating having a blend of a PLA-PEO copolymer and a PLA-PCL copolymer, wherein said coating includes a restenosis inhibiting agent selected from the group consisting of paclitaxel, paclitaxel analogues, paclitaxel derivatives, and combinations thereof mixed therein, such that said agent is released over a time period longer than would be released by said PLA-PEO copolymer alone, and released over a time period shorter than would be released PLA-PCL copolymer alone.
References Cited (Backward Citations)
US3663288A
Cited
US3779792A
Cited
US4047957A
Cited
US4391797A
Cited
US4100309A
Cited
US4119094A
Cited
US4263188A
Cited
US4306998A
Cited
US4387024A
Cited
US4675361A
Cited
US4373009A
Cited
US4459317A
Cited
US4487808A
Cited
US4666437A
Cited
US4548844A
Cited
US4536179A
Cited
US5002582A
Cited
US4492622A
Cited
US4770664A
Cited
US4876126A
Cited
US5037677A
Cited
US4959074A
Cited
US4642267A
Cited
US5057371A
Cited
US4780352A
Cited
US4923464A
Cited
US4705709A
Cited
US5102417A
Cited
US4748986A
Cited
US4768507A
Cited
US4833014A
Cited
US4721117A
Cited
US4692352A
Cited
US4867173A
Cited
US5037656A
Cited
US5092885A
Cited
US4734092A
Cited
US5211183A
Cited
US5527337A
Cited
US4969890A
Cited
US5304140A
Cited
US5080683A
Cited
US4841976A
Cited
US5019096A
Cited
US4980231A
Cited
US4943460A
Cited
US4925698A
Cited
US4884579A
Cited
US5007928A
Cited
US5079093A
Cited
US5067489A
Cited
US5902332A
Cited
US5470829A
Cited
US5091205A
Cited
US5080924A
Cited
US5069226A
Cited
US5128170A
Cited
US4964409A
Cited
US4994071A
Cited
US5026607A
Cited
US5129890A
Cited
US5049403A
Cited
US5066705A
Cited
US5084315A
Cited
US5545208A
Cited
US5008363A
Cited
US5107852A
Cited
US5569463A
Cited
US5447724A
Cited
US5069217A
Cited
US5040543A
Cited
US5102401A
Cited
US5222971A
Cited
US5449372A
Cited
US5240994A
Cited
US5250613A
Cited
US5160790A
Cited
US5290585A
Cited
US5674192A
Cited
US5304121A
Cited
US5370614A
Cited
US5324261A
Cited
US5102402A
Cited
US5266359A
Cited
US5512055A
Cited
US5241970A
Cited
US5105010A
Cited
US5213111A
Cited
US5275173A
Cited
US5514154A
Cited
US5243996A
Cited
US5423885A
Cited
US5283063A
Cited
US5755769A
Cited
US5443496A
Cited
US5697967A
Cited
US5282823A
Cited
US5591227A
Cited
US5217026A
Cited
US5383928A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-07-09 | 2005-01-08 | 2005-07-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-07-09 | 2009-01-08 | 2009-07-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-07-09 | 2013-01-08 | 2013-07-10 | $7700.00 | Window Closed / Lapsed |